All Articles
Late-Breaking HOPA News: T-cell Malignancies with CAR T-cell therapy
In November 2023, the FDA announced their investigation of reports of T-cell lymphomas from clinical trials and post-marketing adverse event data sources for CAR T-cell immunotherapies. In January 2024, the FDA issued Safety Labeling Change notification.
Pharmacist’s Application to Practice: Nirogacestat (Ogsiveo)
Brooke Lochridge, PharmD ,PGY-2 Oncology Pharmacy Resident, of Tristar Centennial Medical Center, Nashville, TN, and Colleen McCabe, PharmD, BCOP, Oncology Clinical Specialist, Sarcoma & Melanoma from Vanderbilt University Medical Center, Nashville, TN w
Pharmacist’s Application to Practice: Eflornithine for High-Risk Neuroblastoma
Taylor Gullickson, PharmD, PGY1 Pharmacy Resident and Alexis Kuhn, PharmD, BCOP, Pediatric Oncology Pharmacist, from Mayo Clinic Rochester, Minnesota write about Eflornithine for High-Risk Neuroblastoma.
Late-Breaking HOPA News: COMMANDS Study for Myelodysplastic Syndrome
The COMMANDS study was a phase 3, open-label, multicenter, randomized controlled trial. Patients were eligible for enrollment if they were 18 years or older, diagnosed with very low risk, low risk or intermediate risk MDS, ESA-naïve, and requiring red blo
